Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121971 | 0.80 | CDK2 (0.70) | CDK2BRAFKDRFLT1FLT4 | |
| SCHEMBL8298737 | 0.78 | ABCG2 (0.52) | ABCG2SLC2A1SYKCDC7KDR | |
| SCHEMBL6662179 | 0.78 | CDK2 (0.66) | CDK2BRAFABCG2SYKKDR | |
| SCHEMBL6281968 | 0.77 | CYP1A2 (0.48) | — | |
| SCHEMBL5000792 | 0.77 | BRAF (0.55) | BRAFABCG2SLC2A1SYKKDR | |
| SCHEMBL4997476 | 0.76 | BRAF (0.64) | BRAFABCG2KDR | |
| SCHEMBL1678613 | 0.76 | CDK2 (1.00) | CDK2BRAFSCN9A | |
| SCHEMBL4992499 | 0.76 | BRAF (0.60) | BRAFABCG2SYKKDR | |
| SCHEMBL4162147 | 0.76 | ABCG2 (0.48) | BRAFABCG2SLC2A1SYKEGFR | |
| SCHEMBL21257473 | 0.74 | CDK2 (0.60) | CDK2BRAFKDRPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | disclosed |
| WO-2009089042-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | MAP3K1, MAP3K15, MAP3K5 | CDK2 67/4885BRAF 73/4885ABCG2 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.